Skip to main content

National Institute of Allergy and Infectious Diseases — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

64
Companies
$399.1M
Total invested
$6.2M
Avg. check
17
Industries
Biotechnology 22Health Care 12Pharmaceutical 7Biopharma 6Medical 5Therapeutics 5+11 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 64
HDT Bio
September 2026

HDT Bio is a developer of RNA vaccines and therapeutics based on LION formulation technology.

Biopharma · Seattle$5.2M Grant
ReAlta Life Sciences
April 2026

ReAlta is a clinical-stage biotech company that develops a new class of drugs to address life-threatening diseases.

Biotechnology · Norfolk$40.0M Undisclosed
ILiAD Biotechnologies
February 2026

ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.

Biotechnology · New York$115.0M Series D
Trethera
December 2025

Trethera is a biotechnology company that discovers and develops small molecules that control DNA replication and integrity.

Biotechnology · Beverly Hills$2.7M Grant
Daré Bioscience
November 2025

Daré Bioscience is a biopharmaceutical company that develops and commercializes therapies for women's health.

Biopharma · San Diego$3.6M Grant
Scanogen
September 2025

Scanogen is a molecular diagnostic company.

Biotechnology · Windsor Mill$2.9M Grant
Lactiga
September 2025

Lactiga is a biotherapeutics company advancing its patented biologics to transform the anti-infective sector and protect vulnerable patients

Biotechnology · PrincetonGrant
Sunflower Therapeutics
September 2025

Sunflower Therapeutics is a biotech company that delivers next-generation protein manufacturing solutions.

Biotechnology · Hingham$300K Grant
MiNK Therapeutics
June 2025

MiNK Therapeutics is a biopharmaceutical company developing allogeneic iNKT cell therapies and immune technologies for treatment.

Biopharma · New YorkGrant
Calder Biosciences
May 2025

Calder Biosciences is a groundbreaking biotechnology and molecular engineering firm developing next generation subunit vaccines

Biopharma · New YorkSeed
Versatope Therapeutics
May 2025

Versatope is an immuno-therapeutic company that uses a biotechnology platform to delivery immunity.

Biotechnology · Lowell$200K Grant
Osivax
March 2025

Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.

Biotechnology · Lyon$10.5M Series B
Resvita Bio
September 2024

Resvita Bio develops and manufactures engineered probiotics for use in treatment if skin related diseases including cancer.

Biotechnology · Berkeley$2.0M Grant
Moonlight Therapeutics
August 2024

Moonlight Therapeutics is focused on developing safe, effective, and patient-friendly treatments for food allergies.

Biotechnology · Atlanta$2.4M Venture - Series Unknown
Acenxion Biosystems
August 2024

Acenxion Biosystems is a privately funded company developing automated medical diagnostic systems for precision medicine.

Biotechnology · Lawrence$1.1M Seed
Aldatu Biosciences
August 2024

Aldatu Biosciences is the leader in adaptive PCR diagnostics for global health and emerging diseases.

Biotechnology · Watertown$3.0M Grant
Clairyon
June 2024

Clairyon is a healthcare technology company that specializes in outpatient monitoring, predictive analytics, and quality reporting services.

Artificial Intelligence (AI) · San Diego$1.0M Grant
TFF Pharmaceuticals
April 2024

TFF Pharmaceuticals is a clinical-stage biopharmaceutical company that develops drug products.

Biopharma · Austin$4.8M Post-IPO Equity
Siolta Therapeutics
March 2024

Siolta Therapeutics is a biotech company focused on developing therapeutic microbial consortia to prevent and treat inflammatory diseases.

Biotechnology · San Carlos$12.0M Series C
Phase Genomics
March 2024

Phase Genomics develops a biotechnology platform for new discoveries in agriculture, human health, and industrial biology industries.

Bioinformatics · Seattle$1.5M Grant
Blacksmith Medicines
February 2024

Blacksmith Medicines developing medicines targeting metal-dependent enzymes found in human physiology.

Biotechnology · San Diego$3.3M Grant
Omniose
September 2023

Omniose is an early stage biotechnological company.

Biotechnology · St Louis$3.0M Grant
Ceramedix Holding
August 2023

Ceramedix Holding is a biotherapeutics company that develops antibody-based drugs with the aim of addressing novel diseases.

Biopharma · New York$3.0M Grant
Exavir Therapeutics
August 2023

Exavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections.

Biotechnology · San Francisco$3.0M Grant

Where National Institute of Allergy and Infectious Diseases invests

Biotechnology22
Health Care12
Pharmaceutical7
Biopharma6
Medical5
Therapeutics5

About National Institute of Allergy and Infectious Diseases's portfolio

How many companies has National Institute of Allergy and Infectious Diseases invested in?▸

National Institute of Allergy and Infectious Diseases has invested in 64 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does National Institute of Allergy and Infectious Diseases invest in?▸

National Institute of Allergy and Infectious Diseases's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Biopharma, Medical. The firm invests across 17 different industry categories.

What is National Institute of Allergy and Infectious Diseases's largest investment?▸

Among tracked funding rounds, ILiAD Biotechnologies received $115.0M in a Series D round. National Institute of Allergy and Infectious Diseases's total known invested capital is $399.1M.

What is the average investment size for National Institute of Allergy and Infectious Diseases?▸

National Institute of Allergy and Infectious Diseases's average investment size is $6.2M across its portfolio of 64 companies.

What are National Institute of Allergy and Infectious Diseases's most recent investments?▸

Recent National Institute of Allergy and Infectious Diseases portfolio additions include HDT Bio, ReAlta Life Sciences, ILiAD Biotechnologies, Trethera, Daré Bioscience. These companies were founded in 2020 or later.

Reach the founders behind these 64 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →